Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/01/2013 | 01:27pm CEST
   By Melodie Warner 
 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at [email protected]

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
Stocks mentioned in the article
ChangeLast1st jan.
ILLUMINA -1.70% 266.22 Delayed Quote.23.96%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 3.70% 7962 Delayed Quote.17.47%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
05/24JOHN WOOD : Wins "Multi-Million" Dollar Contract With Teva Biotech
AQ
05/23TEVA PHARMACEUTICAL INDUSTRIES : FDA to respond to Teva migraine drug applicatio..
AQ
05/23TEVA PHARMACEUTICAL INDUSTRIES : Confirms September PDUFA Date for Fremanezumab
BU
05/21ACTELION : Teva on FDA name and shame list
AQ
05/21TEVA PHARMACEUTICAL INDUSTRIES : Israel’s Teva on FDA blacklist of drugmak..
AQ
05/18TEVA PHARMACEUTICAL INDUSTRIES : CORRECTING and REPLACING Teva Announces Publica..
PU
05/18TEVA PHARMACEUTICAL INDUSTRIES LTD ( : Free Stock Performance Review on Teva Pha..
AC
05/18FDA approves Aimovig as first CGRP inhibitor for migraines
AQ
05/18Hikma reaffirms full-year revenue forecast, cites better generics business
RE
05/17BERKSHIRE HATHAWAY : Buffett's Berkshire Hathaway doubles its stake in Teva
AQ
More news
News from SeekingAlpha
05/25My Favorite Rule - Don't Put All Your Eggs In One Basket 
05/24Amarin settles Vascepa patent challenge with Teva; shares up 2% after hours 
05/24Shopify Cannot Be Killed Easily - Cramer's Lightning Round (5/23/18) 
05/24INSTITUTIONAL TOP IDEAS SERIES : Perceptive Advisors 
05/22Antares Pharma, Excellent Risk-Reward Profile 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 1,12x
Capi. / Sales 2019 1,12x
Capitalization 21 909 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 19,5 $
Spread / Average Target -9,6%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED17.47%21 909
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970